Latest Breaking News On - Blue earth therapeutic - Page 1 : comparemela.com

Blue Earth Therapeutics Announces Promising Results from Preclinical Evaluation of Synergistic Drug Combinations with Radiopharmaceutical 177Lu-rhPSMA-10 1 for Treatment of Prostate Cancer

177Lutetium-labeled radiohybrid Prostate-Specific Membrane Antigen (177Lu-rhPSMA-10.1) is in development as a highly optimized, next generation therapeutic radiopharmaceutical

United statesSan diegoDavide gaudenScintomics gmbTechnical university of munichAmerican association for cancer researchBlue earth therapeuticsAmerican associationCancer researchAnnual meetingProstate specific membrane antigen targetedBlue earth therapeuticChief executive officerBlue earthRadiohybrid prostate specific membrane antigenTechnical university

Blue Earth Therapeutics Announces Publication of Results from Independent Clinical Experience with 177Lu-rhPSMA-10 1 in Treatment of Metastatic Castrate Resistant Prostate Cancer

First reported clinical results from independent clinical experience by University of Augsburg demonstrated encouraging preliminary data for 177Lu-rhPSMA-10.1

United statesConstantin lapaDavid gaudenDepartment of nuclear medicineUniversity hospital augsburgJournal of nuclear medicineDrug administrationUniversity hospitalBlue earth therapeuticsEfficacy dataMetastatic prostate cancerNuclear medicineProstate specific membrane antigen targetedBlue earth therapeuticTherapeutic indexChief executive officer

Blue Earth Therapeutics Announces Publication of Results from Independent Clinical Experience with 1

– First reported clinical results from independent clinical experience by University of Augsburg demonstrated encouraging preliminary data for 177Lu-rhPSMA-10.1 –– 177Lutetium-labeled radiohybrid (rh) Prostate-Specific Membrane Antigen (177Lu-rhPSMA-10.1) is now in clinical development as a highly optimized, next ge.

United kingdomUnited statesMike beyerPriscilla harlanDavid gaudenClare gidleyConstantin lapaUniversity hospital augsburgCorporate communicationsUniversity hospitalUniversity of augsburgDepartment of nuclear medicineBracco groupJournal of nuclear medicineDrug administrationSam brown inc

Blue Earth Therapeutics Announces Results of Early Clinical and Preclinical Studies of Investigational 177Lu-rhPSMA-10 1 in Treatment of Prostate Cancer

Blue Earth Therapeutics Announces Results of Early Clinical and Preclinical Studies of Investigational 177Lu-rhPSMA-10 1 in Treatment of Prostate Cancer
itnonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itnonline.com Daily Mail and Mail on Sunday newspapers.

Flu itNordrhein westfalenUnited kingdomUnited statesRalph bundschuhDavide gaudenSv gbqScintomics gmbCaroline foxtonDrug administrationSociety of nuclear medicineUniversity of augsburgUniversity hospital augsburgNuclear medicineTechnical university of munichBlue earth therapeutics

Blue Earth Therapeutics Announces Results of Early Clinical and Preclinical Studies of Investigational ¹⁷⁷Lu-rhPSMA-10 1 in Treatment of Prostate Cancer

Blue Earth Therapeutics Announces Results of Early Clinical and Preclinical Studies of Investigational ¹⁷⁷Lu-rhPSMA-10 1 in Treatment of Prostate Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomFlu itNordrhein westfalenUnited statesPriscilla harlanMike beyerSv gbqDavide gaudenRalph bundschuhScintomics gmbCaroline foxtonClare gidleyUniversity hospital augsburgSociety of nuclear medicineDrug administrationUniversity of augsburg